News + Filings Transactions
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
|
Myszkowski Kenneth Allen
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
06/29/2023 |
4
| Myszkowski Kenneth Allen (CFO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.
Txns:
| Sold 15,000 shares
@ $36.2, valued at
$543k
|
|
01/05/2023 |
4
| Myszkowski Kenneth Allen (CFO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.
Txns:
| Granted 60,000 shares
@ $0 |
|
12/30/2022 |
4
| Myszkowski Kenneth Allen (CFO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.
Txns:
| Sold 30,625 shares
@ $40, valued at
$1.2M
|
|
09/30/2022 |
5
| Myszkowski Kenneth Allen (CFO) has filed a Form 5 on ARROWHEAD PHARMACEUTICALS, INC. |
01/06/2022 |
4
| Myszkowski Kenneth Allen (CFO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.
Txns:
| Sold 15,908 shares
@ $60.5, valued at
$962.4k
Sold 16,528 shares
@ $62, valued at
$1M
Sold 3,778 shares
@ $63.17, valued at
$238.7k
Sold 3,786 shares
@ $63.95, valued at
$242.1k
|
|
01/04/2022 |
4
| Myszkowski Kenneth Allen (CFO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.
Txns:
| Granted 60,000 shares
@ $0 |
|
01/12/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/07/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
11/12/2020 |
4
| Myszkowski Kenneth Allen (CFO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.
Txns:
| Sold 25,840 shares
@ $69.04, valued at
$1.8M
Sold 17,665 shares
@ $69.86, valued at
$1.2M
Exercised 43,505 options to buy
@ $14.54, valued at
$632.6k
|
|
10/22/2020 |
4
| Myszkowski Kenneth Allen (CFO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.
Txns:
| Sold 29,166 shares
@ $54.04, valued at
$1.6M
Exercised 29,166 options to buy
@ $6.15, valued at
$179.4k
|
|
02/27/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/23/2020 |
4
| Myszkowski Kenneth Allen (CFO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.
Txns:
| Sold 6,397 shares
@ $47.07, valued at
$301.1k
Sold 6,432 shares
@ $47.93, valued at
$308.3k
Sold 10,554 shares
@ $49.07, valued at
$517.9k
Sold 2,800 shares
@ $49.98, valued at
$139.9k
Sold 10,680 shares
@ $51.11, valued at
$545.9k
Sold 3,450 shares
@ $52.13, valued at
$179.8k
Exercised 33,351 options to buy
@ $5.19, valued at
$173.1k
|
|
01/08/2020 |
4
| Myszkowski Kenneth Allen (CFO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.
Txns:
| Sold 7,593 shares
@ $59.6, valued at
$452.5k
Sold 11,907 shares
@ $60.4, valued at
$719.2k
Sold 500 shares
@ $60.95, valued at
$30.5k
|
|
01/03/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
11/07/2019 |
4
| Myszkowski Kenneth Allen (CFO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.
Txns:
| Exercised 12,649 options to buy
@ $5.19, valued at
$65.6k
|
|
11/01/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/03/2019 |
4
| Myszkowski Kenneth Allen (CFO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.
Txns:
| Exercised 15,000 options to buy
@ $4.6, valued at
$69k
Exercised 20,000 options to buy
@ $5.19, valued at
$103.8k
|
|
05/22/2019 |
4
| Myszkowski Kenneth Allen (CFO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.
Txns:
| Sold 27,071 shares
@ $22, valued at
$595.6k
|
|
02/20/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/18/2019 |
4
| Myszkowski Kenneth Allen (CFO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.
Txns:
| Sold 81,875 shares
@ $14.55, valued at
$1.2M
|
|
01/03/2019 |
4
| Myszkowski Kenneth Allen (CFO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.
Txns:
| Granted 85,000 shares
@ $0 Sold 8,333 shares
@ $11.98, valued at
$99.8k
|
|
09/10/2018 |
4
| Myszkowski Kenneth Allen (CFO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.
Txns:
| Sold 25,000 shares
@ $18, valued at
$450k
Sold 20,000 shares
@ $21.01, valued at
$420.2k
Exercised 25,000 options to buy
@ $2.62, valued at
$65.5k
Exercised 20,000 options to buy
@ $4.75, valued at
$95k
|
|
06/20/2018 |
4
| Myszkowski Kenneth Allen (CFO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.
Txns:
| Sold 20,000 shares
@ $14.01, valued at
$280.2k
Exercised 20,000 options to buy
@ $2.01, valued at
$40.2k
|
|
06/01/2018 |
4
| Myszkowski Kenneth Allen (CFO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.
Txns:
| Sold 1,400 shares
@ $11, valued at
$15.4k
Sold 12,600 shares
@ $11, valued at
$138.6k
Exercised 1,400 options to buy
@ $2.01, valued at
$2.8k
Exercised 12,600 options to buy
@ $2.01, valued at
$25.3k
|
|
03/27/2018 |
4
| Myszkowski Kenneth Allen (CFO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.
Txns:
| Sold 20,000 shares
@ $8, valued at
$160k
Exercised 20,000 options to buy
@ $2.01, valued at
$40.2k
|
|
03/05/2018 |
4
| Myszkowski Kenneth Allen (CFO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.
Txns:
| Paid exercise price by delivering 8,208 shares
@ $6.66, valued at
$54.7k
|
|
01/03/2018 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
10/06/2017 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities: |
01/04/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
08/26/2016 |
4/A
| Myszkowski Kenneth Allen (CFO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.
Txns:
| Sold 13,100 shares
@ $8, valued at
$104.8k
Sold 6,900 shares
@ $8, valued at
$55.2k
Exercised 13,100 options to buy
@ $2.01, valued at
$26.3k
Exercised 6,900 options to buy
@ $2.01, valued at
$13.9k
|
|
08/24/2016 |
4
| Myszkowski Kenneth Allen (CFO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.
Txns:
| Sold 13,100 shares
@ $8, valued at
$104.8k
Sold 6,900 shares
@ $8, valued at
$55.2k
Exercised 13,100 options to buy
@ $2.01, valued at
$26.3k
Exercised 6,900 options to buy
@ $2.01, valued at
$13.9k
|
|
03/08/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
02/09/2016 |
4
| Myszkowski Kenneth Allen (CFO) has filed a Form 4 on ARROWHEAD RESEARCH CORP
Txns:
| Paid exercise price by delivering 13,048 shares
@ $3.46, valued at
$45.1k
|
|
|
|
|